

S 3558

Prohibiting Foreign Access to American Genetic Information Act of 2024

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Government Operations and Politics

Introduced: Dec 20, 2023

Current Status: Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.

Latest Action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 521. (Sep 23, 2024)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/3558>

Sponsor

Name: Sen. Peters, Gary C. [D-MI]

Party: Democratic • State: MI • Chamber: Senate

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Hagerty, Bill [R-TN]	R · TN		Dec 20, 2023
Sen. Romney, Mitt [R-UT]	R · UT		Jan 24, 2024
Sen. Marshall, Roger [R-KS]	R · KS		Jan 25, 2024
Sen. Lankford, James [R-OK]	R · OK		Jan 30, 2024
Sen. Scott, Rick [R-FL]	R · FL		Jan 30, 2024
Sen. Hawley, Josh [R-MO]	R · MO		Jan 31, 2024
Sen. Warner, Mark R. [D-VA]	D · VA		Feb 12, 2024
Sen. Rubio, Marco [R-FL]	R · FL		Apr 8, 2024
Sen. Britt, Katie Boyd [R-AL]	R · AL		May 23, 2024
Sen. Hoeven, John [R-ND]	R · ND		Sep 10, 2024

Committee Activity

Committee	Chamber	Activity	Date
Homeland Security and Governmental Affairs Committee	Senate	Reported By	Sep 23, 2024

Subjects & Policy Tags

Policy Area:

Government Operations and Politics

Related Bills

Bill	Relationship	Last Action
118 HR 8333	Related bill	<b>Sep 10, 2024:</b> Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.

Specifically, the bill prohibits executive agencies from (1) procuring or obtaining any biotechnology equipment or service produced or provided by a biotechnology company of concern, or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes.

A *biotechnology company of concern* includes BGI, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of such entities, and any entity that

- is subject to the jurisdiction, direction, control, or operates on behalf of the government of a foreign adversary;
- is involved in the manufacturing, distribution, provision, or procurement of a biotechnology equipment or service; and
- poses a risk to U.S. national security based on specified activities.

Executive agencies may waive the prohibitions on a case-by-case basis under specified circumstances.

The Office of Management and Budget must develop and periodically update a list of the entities that constitute biotechnology companies of concern.

### **Actions Timeline**

---

- **Sep 23, 2024:** Committee on Homeland Security and Governmental Affairs. Reported by Senator Peters with an amendment in the nature of a substitute. With written report No. 118-229.
- **Sep 23, 2024:** Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
- **Mar 6, 2024:** Committee on Homeland Security and Governmental Affairs. Ordered to be reported with an amendment in the nature of a substitute favorably.
- **Dec 20, 2023:** Introduced in Senate
- **Dec 20, 2023:** Read twice and referred to the Committee on Homeland Security and Governmental Affairs.